000K utf8 1100 2023$c2023-10-31 1500 eng 2050 urn:nbn:de:hbz:465-20240808-133942-7 2051 10.1177/17562864231207508 3000 Chae, Woon Hyung 3010 Dammann, Philipp 3010 Darkwah Oppong, Marvin 3010 Deuschl, Cornelius 3010 Forsting, Michael 3010 Frank, Benedikt 3010 Glas, Martin 3010 Hüsing, Anika 3010 Kleinschnitz, Christoph 3010 Köhrmann, Martin 3010 Kühne Escolà, Jordi 3010 Li, Yan 3010 Milles, Lennart Steffen 3010 Vössing, Annika 4000 Treatment of acute ischemic stroke in patients with active malignancy$dinsight from a comprehensive stroke center [Chae, Woon Hyung] 4209 Background: Despite the high incidence of acute ischemic stroke (AIS) in cancer patients, there is still no consensus about the safety of recanalization therapies in this cohort. Objectives: In this observational study, our aim was to investigate the bleeding risk after acute recanalization therapy in AIS patients with active malignancy. Methods and Study Design: We retrospectively analyzed observational data of 1016 AIS patients who received intravenous thrombolysis with rtPA (IVT) and/or endovascular therapy (EVT) between January 2017 and December 2020 with a focus on patients with active malignancy. The primary safety endpoint was the occurrence of stroke treatment-related major bleeding events, that is, symptomatic intracranial hemorrhage (SICH) and/or relevant systemic bleeding. The primary efficacy endpoint was neurological improvement during hospital stay (NI). Results: None of the 79 AIS patients with active malignancy suffered from stroke treatment-related systemic bleeding. The increased rate (7.6% versus 4.7%) of SICH after therapy compared to the control group was explained by confounding factors. A total of nine patients with cerebral tumor manifestation received acute stroke therapy, two of them suffered from stroke treatment-related intracranial hemorrhage remote from the tumor, both asymptomatic. The group of patients with active malignancy and the control group showed comparable rates of NI. 4950 https://doi.org/10.1177/17562864231207508$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:hbz:465-20240808-133942-7$xR$3Volltext$534 4961 https://duepublico2.uni-due.de/receive/duepublico_mods_00079270 5051 610 5550 EVT 5550 intracranial bleeding 5550 IVT 5550 malignancy 5550 stroke 5550 systemic bleeding 5550 thrombolysis